<DOC>
	<DOCNO>NCT02762474</DOCNO>
	<brief_summary>This trial go evaluate efficacy safety IMRT / nab-TP chemotherapy unresectable esophageal cancer , investigate optimal concurrent chemotherapy regimen local advance unresectable esophageal cancer patient .</brief_summary>
	<brief_title>Trial Concurrent Chemoradiotherapy Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description>Esophageal carcinoma sixth leading cause cancer-related mortality cancer 407000 death eighth common cancer worldwide . Concurrent chemoradiotherapy remain mainstay treatment locally advanced esophageal cancer . Paclitaxel combine radiotherapy high efficiency achieve encouraging result . Compared paclitaxel , nab-paclitaxel low toxicity , low allergy tolerance well paclitaxel . According pre-clinical result , investigator design prospective study , combine nab-paclitaxel cisplatin concurrent chemoradiotherapy patient locally advanced esophageal cancer , evaluate tolerability efficacy . design enrol 30 patient , end point include toxicity , progression-free survival overall survival .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1. inoperable locally advanced histologically confirm esophageal cancer ( T3N0M0TxNxM1a（AJCC 2002 ) 2 . ECOG performance status scale 01 3. least 1 measurable target lesion 4. white blood count ≥ 3,500/mm3 , absolute neutrophil count ≥ 1,500/mm3 , platelet count ≥ 100,000/mm3 , hemoglobin count ≥ 90 g/dL , serum bilirubin level &lt; 1.5 upper limit normal ( ULN ) institution , aspartate aminotransferase , alanine aminotransferase alkaline phosphatase ≤ 2.5 ULN , serum albumin ≥ 30g/L , serum creatinine ≤ 1.5 ULN ; 5. normal cardiac function severe heart disease . 1. history esophagectomy 2. pregnancy breast feed 3. past history cancer except cured nonmelanoma skin cancer cervical cancer ; 4. concomitant treatment anticancer drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>nab-paclitaxel</keyword>
	<keyword>IMRT</keyword>
	<keyword>esophageal cancer</keyword>
</DOC>